Article
5m Read
March 10, 2026
COMMUNITY AND GLOBAL HEALTH
Whitepaper
9m Read
May 27, 2025
ANTIMICROBIAL STEWARDSHIP
Main Menu
-
Solutions
Back
Cepheid’s Solutions
-
Global Access
-
Testing Everywhere
Back
Testing Everywhere
-
Antibiotic Stewardship
-
Customized Testing for Your Institution
-
Knowing MORE Matters
-
-
Insights
Back
Cepheid’s Insights
-
Webinars
Back
Webinars
-
Cepheid RADAR
Back
Cepheid RADAR
-
Support
Back
Support Center
-
Documents & Technical Resources
-
Troubleshooting and How-tos
-
MyCepheid and Order Support
-
Contact Us
Back
Contact Us
-
-
About Us
Back
About Cepheid
-
Mission and History
Back
Mission and History
-
Our Leadership
Back
Our Leadership
-
Events
Back
Events
-
Distributors
Back
Distributors
-
Business Development Opportunities
-
Innovate with Cepheid
-
Meet the Cepheid Bike
-
News
Back
News
-
Careers
Back
Careers
-
The Need
- Norovirus is highly contagious and is the most common cause of acute gastroenteritis worldwide1,2
- Globally, an estimated 685 million cases of norovirus are seen annually, including 200 million cases amongst children under 51,2
- Norovirus causes an estimated 200,000 deaths per year, including 50,000 child deaths1,2
- Every year, this virus is estimated to cost $60 billion worldwide due to healthcare costs and lost productivity1,2
- Norovirus outbreaks in healthcare institutions require immediate implementation of infection control measures to avoid ward closures1,2
1 Norovirus Burden and trends, CDC https://www.cdc.gov/norovirus/burden.html#worldwide. Accessed November 22, 2023
2 Norovirus introduction. WHO. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/norovirus. Accessed November 22, 2023
2 Norovirus introduction. WHO. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/norovirus. Accessed November 22, 2023
The Solution
- Xpert Norovirus detects genotype I (GI) and genotype II (GII), which are responsible for the majority of infections
- Xpert Norovirus provides rapid results to support timely infection control measures and outbreak response3
- On-demand identification supports outbreak management enabling fast contact tracing to manage onward transmission4
3 Cleary O, et al. Evaluation of the Xpert Norovirus assay for the rapid detection of norovirus genogroups I and II in faecal specimens within a routine laboratory setting. British Journal of Biomedical Science. 2017 Dec:74(3):144-147
4 Salmona M, et al. Laboratory-based strategy using a new marketed polymerase chain reaction assay to manage diarrheic episodes among patients from rehabilitation and long-term care facilities. Am J Infect Control. 2016 Jun 1;44(6):716-8
4 Salmona M, et al. Laboratory-based strategy using a new marketed polymerase chain reaction assay to manage diarrheic episodes among patients from rehabilitation and long-term care facilities. Am J Infect Control. 2016 Jun 1;44(6):716-8
The Impact
In published implementation studies, Xpert Norovirus PCR testing has been evaluated in routine healthcare settings to assess its potential role in supporting timely laboratory diagnosis. These studies report that fast molecular results may support infection control workflows when used as part of established institutional practices.³ ⁵ ⁶ Across reported study sites, implementation of Xpert Norovirus testing was associated with reduced laboratory turnaround times compared to prior diagnostic approaches under those specific conditions. Reported findings included:
- An 89% reduction in turnaround time (from 22 hours to 2.4 hours) within the evaluated study settings⁵
- A reported reduction in unnecessary patient isolation when molecular testing results were incorporated into local infection management decisions⁶
- Estimated operational cost impacts related to bed availability and isolation practices, as described in site‑specific economic analyses⁶
- These outcomes reflect observations from published studies conducted in defined healthcare environments and may vary based on institutional workflows, infection control policies, patient populations, and local resource availability.
3 Cleary O, et al. Evaluation of the Xpert Norovirus assay for the rapid detection of norovirus genogroups I and II in faecal specimens within a routine laboratory setting. British Journal of Biomedical Science. 2017 Dec:74(3):144-147
5 Henningsson AJ, Nilsson Bowers A, Nordgren J, Quttineh M, Matussek A, Haglund S. Rapid diagnosis of acute norovirus-associated gastroenteritis: evaluation of the Xpert Norovirus assay and its implementation as a 24/7 service in three hospitals in Jönköping County, Sweden. Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1867-1871
6 Lyer S, et al. Comparative Evaluation 2 Commercial Norovirus Real-time PCR assays for Hospital Outbreak Management. Federation of Infection society p192 11th-14th Nov. 2013
* 57 minutes with early assay termination for positive results
#values are associated with single site implementation of Xpert Norovirus
5 Henningsson AJ, Nilsson Bowers A, Nordgren J, Quttineh M, Matussek A, Haglund S. Rapid diagnosis of acute norovirus-associated gastroenteritis: evaluation of the Xpert Norovirus assay and its implementation as a 24/7 service in three hospitals in Jönköping County, Sweden. Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1867-1871
6 Lyer S, et al. Comparative Evaluation 2 Commercial Norovirus Real-time PCR assays for Hospital Outbreak Management. Federation of Infection society p192 11th-14th Nov. 2013
* 57 minutes with early assay termination for positive results
#values are associated with single site implementation of Xpert Norovirus